Best Lentiviral Vector CDMOs in United States

Last updated: 2026-09-15 · updated as new inspection, certificate, and trial data enters the platform

← All Lentiviral CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

For US-manufactured lentiviral vector programs, Thermo Fisher Scientific, AGC Biologics, and Cincinnati Children's Vector Production Facility lead CDMO Signal's ranking of lentiviral vector CDMOs with confirmed US facilities. Filtered from the global directory of 36 scored lentiviral vector CDMOs to 4 with US manufacturing presence. US-based manufacturing carries specific advantages for sponsors filing under FDA jurisdiction: FDA inspection records — which form the core of the Signal Score's Quality Compliance pillar — apply directly, and QP release complexity common to EU-manufactured material does not apply. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Lentiviral vectors are the workhorse of ex vivo gene therapy — used to engineer T cells for CAR-T, TCR programs, and to modify hematopoietic stem cells for inherited disorders. Because the vector integrates into the genome of patient-bound cells, lentiviral manufacturing carries the regulatory weight of a critical starting material under full GMP, mandatory replication-competent lentivirus (RCL) testing, and BSL-2 containment throughout production.

Selecting a lentiviral vector CDMO comes down to five buyer-critical dimensions: BSL-2 containment maturity and site inspection history on lentivirus specifically, a scalable suspension (or well-run adherent) platform, qualified titer + potency + RCL assays, capacity headroom at your target dose × patient volume, and defensible tech-transfer support. The rankings below score each CDMO on FDA inspection classifications, EMA/MHRA GMP density, ClinicalTrials.gov sponsor breadth, and monitored capacity signals — a composite that reflects the regulatory record and operational depth needed for material that lands in patient-bound cells.

FDA inspection outcomes across these CDMOs: 14 NAI (no action), 16 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (27), Denmark (18), UNITED KINGDOM (17), Germany (5), France (4).

Last updated 2026-09-15. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	TF Thermo Fisher Scientific Plainville, MA · Alachua, FL · Cambridge, MA	81.0	100.0	6 insp · 10 GMP	Available	2 programs
2	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	78.6	100.0	2 insp · 23 GMP	Available	2 programs
3	CI Cincinnati Children's Vector Production Facility Cincinnati, OH	75.2	100.0	1 insp · 0 GMP	—	1 programs
4	NR National Resilience San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA	74.5	98.0	1 insp · 0 GMP	Available	9 programs
5	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	90.9	98.3	8 insp · 11 GMP	Limited	0 programs
6	PB Pharmaron Biologics San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China	86.9	100.0	3 insp · 0 GMP	Available	0 programs
7	BR BioReliance (Merck) Glasgow, UK · Rockville, MD	80.2	97.1	4 insp · 8 GMP	—	0 programs
8	BB bluebird bio Manufacturing Durham, NC	78.5	—	—	—	0 programs
9	AG2 August Bioservices San Carlos, CA	77.5	98.7	1 insp · 0 GMP	—	0 programs
10	LZ Lonza Biologics Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH	73.0	95.7	1 insp · 0 GMP	Limited	0 programs
11	VE Vigene Biosciences Rockville, MD	72.5	—	—	—	0 programs
12	GZ Genezen Indianapolis, IN · Lexington, MA	71.5	85.8	3 insp · 0 GMP	Available	0 programs
13	AN Andelyn Biosciences Columbus, OH	63.0	—	—	Available	0 programs
14	GF GeneFab Alameda, CA and South San Francisco	61.5	—	—	Available	0 programs
15	MA Matica Biotechnology College Station, TX	59.0	—	—	Available	0 programs
16	VB VintaBio Cambridge, MA	59.0	—	—	—	0 programs
17	WB Waisman Biomanufacturing Madison, WI	59.0	—	—	—	0 programs
18	EB ElevateBio BaseCamp Waltham, MA	59.0	—	—	—	0 programs
19	VM Vector BioMed Cambridge, MA	59.0	—	—	—	0 programs
20	Vantage Vector (Demo) Gaithersburg, MD	59.0	—	—	Available	0 programs
21	UB uBriGene Biosciences Shanghai, CN · Boston, MA	56.5	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Lentiviral Vector CDMO

Containment & biosafety

Lentivirus requires BSL-2 manufacturing with segregated suites and validated decontamination. Confirm the site's containment design and replication-competent lentivirus (RCL) testing strategy.

Process platform maturity

Suspension culture scales more cleanly than adherent for larger batches. Ask whether the platform is serum-free and how it performs at your target dose and patient volume.

Analytics & potency

Titer, infectivity, and potency assays drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both are shown in the rankings above and on each profile.

FDA jurisdiction — how the ranking scores US-based CDMOs

The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.

Which US CDMOs also cover EU and UK regulatory geographies?

Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.

How CDMO Signal identifies US manufacturing presence

Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.

Lentiviral Vector CDMOs — Frequently Asked Questions

Who are the top Lentiviral Vector CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Lentiviral Vector CDMOs include Thermo Fisher Scientific, AGC Biologics, Cincinnati Children's Vector Production Facility. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Lentiviral Vector CDMOs have FDA inspection records?

CDMO Signal tracks 10 Lentiviral Vector CDMOs with FDA inspection records and 52 EMA/MHRA GMP certificates across the group.

What should I look for in a lentiviral vector CDMO?

Prioritize BSL-2 containment, a mature suspension platform, qualified titer/potency/RCL assays, and a clean FDA and EMA/MHRA record. Match capacity to your dose and patient volume, and confirm tech-transfer support.

How is lentiviral vector manufacturing different from AAV?

Lentivirus integrates into the host genome and is produced under BSL-2 with RCL testing, typically for ex vivo cell engineering. AAV is non-integrating, made at higher volumes, and used mainly for in vivo gene therapy.

Related modalities

Cell Therapy CDMOs CAR-T CDMOs AAV / Gene Therapy CDMOs

Other Modalities

AAV CAR-T Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector